DE1174015B - Process for the production of a live vaccine against foot and mouth disease - Google Patents

Process for the production of a live vaccine against foot and mouth disease

Info

Publication number
DE1174015B
DE1174015B DEB67299A DEB0067299A DE1174015B DE 1174015 B DE1174015 B DE 1174015B DE B67299 A DEB67299 A DE B67299A DE B0067299 A DEB0067299 A DE B0067299A DE 1174015 B DE1174015 B DE 1174015B
Authority
DE
Germany
Prior art keywords
mouth disease
production
cell cultures
live vaccine
vaccine against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DEB67299A
Other languages
German (de)
Inventor
Dr Anton Mayr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Priority to DEB67299A priority Critical patent/DE1174015B/en
Priority to BR149185/63A priority patent/BR6349185D0/en
Priority to GB20030/63A priority patent/GB1039614A/en
Publication of DE1174015B publication Critical patent/DE1174015B/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Description

Verfahren zur Herstellung einer Lebend-Vaccine gegen Maul- und Klauenseuche Zusatz zur Anmeldung: B 61574 IV a/ 30 h-Auslegeschrift 1 155 881 Gegenstand der Patentanmeldung B 615741V al 30h (deutsche Auslegeschrift 1 155 881) ist ein Verfahren zur Herstellung einer Lebend-Vaccine gegen Maul- und Klauenseuche (MKS), das dadurch gekennzeichnet ist, daß man virulentes MKS-Virus in vorzugsweise primären Zellkulturen so lange kontinuierlich Passagen unterwirft und dadurch modifiziert, daß es sich nach parenteraler, vorzugsweise intramuskulärer Injektion in Klauentieren zwar noch vermehrt, aber keine klinisch erkennbare Erkrankung hervorruft und die abgeschwächten Viren in bekannter Weise zu Vaccinen verarbeitet.Process for the production of a live vaccine against foot and mouth disease Addition to registration: B 61574 IV a / 30 h-Auslegeschrift 1 155 881 subject of Patent application B 615741V al 30h (German Auslegeschrift 1 155 881) is a method for the production of a live vaccine against foot and mouth disease (FMD), which thereby is characterized in that one virulent FMD virus in preferably primary cell cultures as long as it continuously submits passages and thereby modifies them so that it becomes after parenteral, preferably intramuscular, injection in cloven-hoofed animals increases but does not cause any clinically recognizable disease and the weakened Viruses processed into vaccines in a known manner.

In dem genannten Verfahren wird somit das virulente MKS-Virus durch kontinuierliches Passieren in vorzugsweise primären Zellkulturen attenuiert und danach eine Passage zur Herstellung einer MKS-Lebend-Vaccine verwendet. In Kälbernierenkulturen läuft der Attenuierungsvorgang sehr langsam ab, für einen brauchbaren Impfstamm sind sehr viele Passagen notwendig. Bei der Weiterzüchtung bleiben die Eigenschaften dieses Virus allerdings stabil. In the process mentioned, the virulent FMD virus is thus through continuous passage in preferably primary cell cultures and attenuated then a passage used to produce a FMD live vaccine. In calf kidney cultures the attenuation process is very slow for a usable vaccine strain a lot of passages are necessary. With further breeding, the properties remain however, this virus is stable.

Es wurde nun eine weitere Ausgestaltung des Verfahrens nach Patentanmeldung B 615741V al 30 h zur Herstellung einer Lebend-Vaccine gegen Maul-und Klauenseuche gefunden, das dadurch gekennzeichnet ist, daß man für die Abschwächung des Virus Passagen auf Zellkulturen von embryonalen Rindernieren verwendet und das abgeschwächte Virus auf Zellkulturen von Nieren frisch geschlachteter Rinder vermehrt. There has now been a further refinement of the method according to the patent application B 615741V al 30 h for the production of a live vaccine against foot and mouth disease found, which is characterized in that one for attenuating the virus Passages used on cell cultures from embryonic bovine kidneys and the attenuated Virus propagated on cell cultures from kidneys of freshly slaughtered cattle.

Beispiel Aus Nieren von Rinderembryonen werden in bekannter Weise durch Trypsinandauung und Züchtung auf der Glasoberfläche von Kulturgefäßen Zellkulturen hergestellt. Die so vorbereitete Gewebekultur wird mit einem iu0/oigen Extrakt aus Rinderaphthen-MKS-Naturvirus vom Typ C beimpft und nach 18 bis 24 Stunden abgeerntet. Das dabei erhaltene Medium wird von Kultur zu Kultur weiterverimpft. Nach 230 Passagen ist das MKS-Virus attenuiert. Example Bovine embryonic kidneys are produced in a known manner cell cultures through trypsin digestion and cultivation on the glass surface of culture vessels manufactured. The tissue culture prepared in this way is made with an extract of 10% Bovine saphthenic foot-and-mouth disease virus of type C inoculated and harvested after 18 to 24 hours. The medium obtained is further inoculated from culture to culture. After 230 passages the FMD virus is attenuated.

Zur Produktion einer genügend großen Menge des Impfstoffes wird das attenuierte MKS-Virus in Zellkulturen aus Nieren frisch getöteter Kälber weiter- gezüchtet. Nach 16 bis 22 Stunden wird das Kulturmedium geerntet und zu einer Vaccine verarbeitet. In order to produce a large enough amount of the vaccine, the attenuated FMD virus in cell cultures from kidneys of freshly killed calves. bred. After 16 to 22 hours, the culture medium is harvested and processed into a vaccine.

Zur Prüfung der Unschädlichkeit und Wirksamkeit werden sechs Rinder intramuskulär mit der erfindungsgemäß hergestellten Vaccine geimpft. Die Impfdosis beträgt 10 ml. Die Tiere zeigten keine klinisch erkennbare Erkrankung. 2 Wochen nach der Impfung werden die Rinder einer Belastungsinfektion mit dem homologen Rinder-Naturvirus unterworfen. To test the harmlessness and effectiveness, six cattle are used vaccinated intramuscularly with the vaccine prepared according to the invention. The vaccination dose is 10 ml. The animals showed no clinically recognizable disease. 2 weeks After vaccination, the cattle become stress-infected with the homologous bovine natural virus subject.

Die geimpften Rinder bleiben gesund, während vier nicht geimpfte Kontrolltiere, die der gleichen Belastungsinfektion unterzogen wurden, generalisiert erkrankten.The vaccinated cattle remain healthy, while four non-vaccinated control animals, who had been subjected to the same stress infection developed generalized disease.

Claims (1)

Patentanspruch: Verfahren zur Herstellung einer Lebend-Vaccine gegen Maul- und Klauenseuche durch Züchten von virulentem MKS-Virus in vorzugsweise primären Zellkulturen in kontinuierlichen Passagen und Verarbeiten der abgeschwächten Viren zu einer Vaccine nach Patentanmeldung B 61574 IVa/30h (deutsche Auslegeschrift 1155 881, dadurch gekennzeichnet, daß man für die Abschwächung Zellkulturen von embryonalen Rinderzellen verwendet und das abgeschwächte Virus auf Zellkulturen von Nieren frisch geschlachteter Rinder vermehrt. Claim: Process for the production of a live vaccine against Foot and mouth disease by growing virulent foot-and-mouth disease virus in preferably primary ones Cell cultures in continuous passages and processing of the attenuated viruses to a vaccine according to patent application B 61574 IVa / 30h (German Auslegeschrift 1155 881, characterized in that cell cultures of embryonic Bovine cells are used and the attenuated virus is fresh on cell cultures from kidneys slaughtered cattle increased.
DEB67299A 1962-05-18 1962-05-18 Process for the production of a live vaccine against foot and mouth disease Pending DE1174015B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DEB67299A DE1174015B (en) 1962-05-18 1962-05-18 Process for the production of a live vaccine against foot and mouth disease
BR149185/63A BR6349185D0 (en) 1962-05-18 1963-05-16 PROCESS FOR THE PREPARATION OF A LIVE VACCINE AGAINST FOOT-AND-Mouth Disease
GB20030/63A GB1039614A (en) 1962-05-18 1963-05-20 Process for the manufacture of a foot-and-mouth disease vaccine containing a live virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEB67299A DE1174015B (en) 1962-05-18 1962-05-18 Process for the production of a live vaccine against foot and mouth disease

Publications (1)

Publication Number Publication Date
DE1174015B true DE1174015B (en) 1964-07-16

Family

ID=6975472

Family Applications (1)

Application Number Title Priority Date Filing Date
DEB67299A Pending DE1174015B (en) 1962-05-18 1962-05-18 Process for the production of a live vaccine against foot and mouth disease

Country Status (3)

Country Link
BR (1) BR6349185D0 (en)
DE (1) DE1174015B (en)
GB (1) GB1039614A (en)

Also Published As

Publication number Publication date
BR6349185D0 (en) 1973-07-03
GB1039614A (en) 1966-08-17

Similar Documents

Publication Publication Date Title
DE69732407T2 (en) METHOD FOR THE REPLICATION OF INFLUENZA IN CELL CULTURE AND THE INFLUENZA VIRUSES MADE IN THIS METHOD
DE2516274C2 (en) Method of making an attenuated cytomegaly virus vaccine - US Pat
DE69216732T2 (en) Poultry anemia vaccine
DE2817891A1 (en) ND VACCINE AND METHOD FOR THE PRODUCTION THEREOF
DE1924303A1 (en) AEthylaethyleneimine as inactivating agent
DE2717919A1 (en) PROCESS FOR MANUFACTURING A HORSE RHINOPNEUMONIC VACCINE AND VACCINE MANUFACTURED BY THIS PROCESS
DE69730040T2 (en) IN OVO VACCINATION AGAINST NEWCASTLE DISEASE
DE2616407A1 (en) RABIES VACCINE AND METHOD FOR MANUFACTURING IT
DD232822A5 (en) METHOD FOR THE PRODUCTION OF A VIRUS PREPARATION AGAINST MAREKSCHE FLUID DISEASE
DE1198489B (en) Process for the preparation of a vaccine against panleucopenia
DE3784397T2 (en) LIVING VACCINE FOR CHICK INFECTIOUS DISEASES.
DE2538994A1 (en) BACTERIAL VACCINE AND METHOD FOR MANUFACTURING IT
DE1174016B (en) Process for the production of a live vaccine against foot and mouth disease
DE1174015B (en) Process for the production of a live vaccine against foot and mouth disease
DE1617756A1 (en) Method of making a new antiviral vaccine
DE1692043C3 (en) Rhinopneumonitis vaccines and processes for their manufacture
DE2033946C2 (en) Live vaccine against infectious pustular vulvovaginitis [IPV] and infectious bovine rhinotracheitis [IBR]
DE2328579A1 (en) VARICELLA-VACCINE
AT234902B (en) Process for the production of a vaccine against distemper
Hata The Protection of Dogs Against Rabies by Umeno's Method of Preventive Inoculation
EP0025116A1 (en) Method of testing the inactivity of inoculates and harmlessness of blood products as well as the activity of chemotherapeutics or disinfectants against virus hepatitis and method for isolation of hepatitis virus antigen
DE2225548A1 (en) INTRAVENOES COMPATIBLE DAMAGE AND HEPATITIS VACCINE
WO1989005154A1 (en) Process for producing an avirulent cold blood virus
DE2517550C3 (en) Method of preparing a live vaccine for immunizing carnivorous animals against distemper
DE1155881B (en) Process for the production of a live vaccine against foot and mouth disease